New Drug Suppliers to Ease Two Cancer Drug Shortages
TRENTON, N.J. (AP) - Federal regulators say they've approved new suppliers for two crucial cancer drugs, easing critical shortages - at least for the time being - that have patients worried about missing life-saving treatments.
The Food and Drug Administration will temporarily allow importation of a replacement drug for Doxil, a drug for ovarian and other cancers that hasn't been available for new patients for months.
The agency also has approved another supplier for a preservative-free version of methotrexate (METH-oh-TRECKS-ayt), a crucial drug for children with a type of leukemia and for high-dose treatment of bone cancer.
The FDA increasingly has been able to prevent drug shortages by getting advance notice from manufacturers, but about 280 drugs currently are in short supply.
- FDA Panel Supports Continued Testing of Pain Drugs
- FDA Review Favors First Drug for HIV Prevention
- FDA Approves "Plan B" for OTC Sale to Women Ages 15 and Up
- FDA Cracks Down on Illegal Diabetes Remedies
- New FDA Approved Silicone Breast Implants
- Your Health: Treating Breast Cancer With New Technology
- New Study: Breast Cancer Patients Want More Involvement in Treatment
- The Dangers of a Drug Named "Molly "
- Stop Children's Cancer Raises Awareness for Pediatric Cancer
- Weight Loss Drug Belviq Gets Overdue US Launch